Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interventions for Post-Bariatric Hypoglycemia
NCT07878494Not yet recruiting
- Sponsor
- Stanford University
- Start
- Nov 2026
- Primary completion
- Nov 2030
- Countries
- 1
01
Overview
Open-label trial of semaglutide and tirzepatide in post-bariatric hypoglycemia (PBH) (3 arms), sponsored by Stanford University. Primary endpoints: Postprandial Glucose Nadir Following Standardized Test Meals, Plasma Glucose Nadir During the Solid Mixed Meal Tolerance Test at 12 weeks and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NCT07878494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07878494.